勵晶太平洋(00575.HK)旗下生物科技公司與Longenesis就管理整合及聯邦學習方法發展合作
勵晶太平洋(00575.HK)公布,其收購的生物科技公司Deep Longevity與Longenesis展開合作。Deep Longevity主營為可視化AI系統,該系統主要是跟蹤人體分子、細胞、組織、器官、系統、生理和心理水平的衰老速度。此次合作方Longenesis則是領先的同意管理整合安全數據管理公司。
兩家公司通過合作將Longenesis的數據安全系統整合到Deep Longevity開發的名為Young.AI的智能系統。系統是一個基於網絡的老齡化和健康追蹤器,以及一個聯合學習框架的發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.